|کد مقاله||کد نشریه||سال انتشار||مقاله انگلیسی||ترجمه فارسی||نسخه تمام متن|
|5529740||1401705||2017||4 صفحه PDF||سفارش دهید||دانلود کنید|
Background and purposeWe investigated the role of 68Ga-PSMA-PET (PSMA) to determine the location of disease recurrence in those with a rising PSA following definitive external beam radiation treatment (EBRT).Materials and methods538Â men were treated with image guided EBRT to a dose of 78 or 82Â Gy between 2007 and 2014. Patients at least 24Â months post EBRT with biochemical failure (nadirÂ +Â 2) underwent PSMA scanning. Local recurrence (LR) was defined as increased uptake within the prostate or seminal vesicles. Distant disease included lymph node (LN), bone or visceral metastases.Results419Â men formed the study cohort. Median follow-up was 50Â months, 70 patients (17%) had biochemical failure (BF), 13 of whom have died. Of the 57 survivors, 5 had metastases detected on conventional scans; 2 were lost to follow up. 48Â men (of 50 candidates) underwent PSMA; in all cases, the PSMA was unequivocally positive.Of the 48 positive scans, 25 patients (52%) failed beyond the prostate - 5 in bones, 16Â LN, 3 in both, and 1 in the lungs. Fifteen men (31%) failed within the gland and in either LN (11), bones (3), or both (1). Eight (17%) had an isolated LR, which represents 2% of patients managed with definitive EBRT and followed for at least 2Â years.ConclusionsPSMA was positive in all patients with BF. Site of failure following dose-escalated EBRT was generally distant. Isolated LR (on PSMA) occurred in only 8 of 419 patients post-EBRT.
Journal: Radiotherapy and Oncology - Volume 122, Issue 1, January 2017, Pages 99-102